Biomedical Diagnostics Institute (BDI)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2005
  • Initiating Organization: Science Foundation Ireland
  • Initiator Type: Government
  • No disease focus
  • Location: Europe

Abstract

The Biomedical Diagnostics Institute (BDI) is a Science Foundation Ireland Centre for Science, Engineering and Technology (CSET). Established in October 2005, BDI is an academic-business-clinical partnership that sponsors research programs focused on the development of next-generation biomedical diagnostic devices.

Mission

The BDI vision is to transform healthcare by pioneering advances in the science and technology of diagnostics and by translating these advances into clinical use.

BDI’s primary objectives are to

  • sustain and grow a world-renowned center of excellence in biomedical diagnostics
  • pioneer advances in the science and technology of diagnostics
  • translate its research outputs into clinical application by working closely with commercial and clinical partners
  • ensure that its various outputs impart both societal and economic benefits to Ireland
  • develop cost-effective diagnostic devices for low-resource environments
  • provide highly skilled researchers to contribute to a vibrant industry sector
  • stimulate an enduring interest in science and technology in students of all ages, as well as enhance public understanding of science

Focus areas:

  • Point of Care 
  • Home healthcare monitoring
  • Link therapy and monitoring (companion diagnostics)

BDI research addresses major clinical challenges informed by the partnership of clinicians, scientists, and industry. Building on key scientific insights, BDI will apply its established capabilities to create integrated Point-of-Care solutions, which will have major impacts on diagnosing disease and sustaining human health.

Consortium History

Established in October 2005, BDI is an academic-industrial-clinical partnership that carries out cutting-edge research programs focused on the development of next-generation biomedical diagnostic devices.

Financing

BDI was seeded with €19.1 million from Science Foundation Ireland and associated funding from industry partners.

Intellectual Property

BDI has generated a strong portfolio of intellectual property (IP), borne out of the diverse technical disciplines that come together in its research strands. The BDI IP portfolio includes cutting-edge devices and methodologies in microfluidics, molecular assays and signal detection, novel biomarkers of disease, and know-how pertaining to the generation and optimization of customized antibodies.

Impact/Accomplishment

BDI has generated a portfolio of IP created through the collaborations. Several of its inventions have made it to the commercial market with CE Marking.

Points of Contact

Dr. Georgina Murphy
IP Manager
phone: 01 700 8919
email: georgina.murphy@invent.dcu.ie

Dr. Conor Burke
Associate Director (Commercialisation)
Biomedical Diagnostics Institute, DCU
phone: +353 1 700 8061
fax: +353 1 700 8021
email: conor.burke@dcu.ie

Sponsors & Partners

Alere

Analog Devices Inc.

Becton Dickinson and Co.

Biosurfit S.A.

Dublin City University

Galway University Hospital

Inverness Medical Innovations

Millipore

National University of Ireland, Galway

Royal College of Surgeons in Ireland

St. James Hospital

The Tyndall National Institute at University College, Cork

Trinity College, Dublin


Last Updated: 04/06/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.